Pharma & Biotech Mergers & Acquisitions News
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Confirming an option agreement earlier this year, Indian pharma major Lupin via its US subsidiary, said today that it has now acquired Symbiomix Therapeutics. 12 October 2017
Pharmaceutical
In another Big Pharma move to realign their operations, US giant Pfizer yesterday announced that it is reviewing strategic alternatives for its Consumer Healthcare business. 11 October 2017
Pharmaceutical
Kitov Pharmaceuticals has acquired an additional 27% stake in TyrNovo, a privately-held developer of novel small molecules in the oncology therapeutic field, from unaffiliated minority shareholders, also based in Israel. 6 October 2017
Pharmaceutical
An analysis from the investment research firm Zacks has considered the impact that US President Donald Trump’s proposed tax reforms could have on large-cap pharma companies based in the USA. 2 October 2017
Pharmaceutical
News last week attracted a great deal of comment included Neos Therapeutics gaining US Food and Drug Administration for its attention deficit hyperactivity disorder (ADHD) drug Adzenys. Also garnering attention were: Ultragenyx’ rival bid to acquire Dimension Therapeutics; supplemental approval for Ipsen’s Somatuline Depot; an FDA safety alert on Intercept Pharmaceuticals’ Ocaliva; and a Phase III success for Nabriva’s lefamulin 23 September 2017
Biotechnology
USA-based Catalent has reached an agreement to acquire Bloomington, Indiana-based Cook Pharmica, an integrated provider of drug substance and drug product manufacturing and related services. 19 September 2017
Biotechnology
Shares in Dimension Therapeutics, a USA-based gene therapy company focused on rare diseases, had rocketed by nearly 38% to $5.76 by Monday lunchtime amid news of a potential takeover to rival the bid made by the biotech firm Regenxbio. 18 September 2017
Biotechnology
Inotek Pharmaceuticals and USA-based gene therapy start-up Rocket Pharmaceuticals have entered into a definitive merger agreement. 13 September 2017
Pharmaceutical
Specialty pharma firm Clinigen Group and fellow London-listed CSO Quantum Pharma have agreed the terms of a takeover deal. 13 September 2017
Biotechnology
USA-based holding company PDL BioPharma has appointed Dominique Monnet to the position of president. 12 September 2017
Pharmaceutical
Deals and rumors returned to the pharma mergers and acquisitions world in August after a quiet summer, with one in particular grabbing the headlines. 6 September 2017
Biotechnology
Merck & Co has announced that it will acquire Rigontec, a Germany-based leader in retinoic acid-inducible gene I (RIG-I) targeting therapeutics. 6 September 2017
Pharmaceutical
Shares in German life sciences company Merck KGaA had climbed by more than 3% to 95.10 euros ($113) by lunchtime on Tuesday after the firm announced it was preparing strategic options for its Consumer Health business. 5 September 2017
Biotechnology
China-based biotech 3SBio (HKG: 1530) has entered into an agreement to acquire Canadian firm Therapure Biopharna’s contract development and manufacturing (CDMO) business and certain rights to plasma products and technology for the Chinese market. 4 September 2017
Pharmaceutical
Without doubt, the biggest piece of news to drop last was the decision of US Biotech major Gilead Sciences to make an acquisition, that of Kite Pharma, which investors have been angling for, given that the company’s magnificent anti-virals blockbuster platform was beginning to fall apart because its latest hepatitis C drugs were actually “curing” the conditions – a self eliminating market. On the regulatory front, the biggest piece of news was the Food and Drug Administration approval of the first CAR-T cell therapy, Novartis’ Kymriah. Novartis also reported some significant new data on its canakinumab. Additionally attracting comment was new data on Bayer’s Xarelto and the acquisition of Dimension Therapeutics by Regenxbio. 3 September 2017
Pharmaceutical
Daiichi Sankyo was not approached by Anglo-Swedish drugmaker AstraZeneca over a takeover. 1 September 2017
Generics
Following a public comment period, the Federal Trade Commission (FTC) has approved a final order designed to remedy the anticompetitive effects resulting from Baxter International’s proposed $625 million acquisition of India-based Claris Lifesciences’ injectable drugs business. 31 August 2017
Biotechnology
US biotech Regenxbio has entered a definitive deal to acquire Dimension Therapeutics in an all-stock transaction for an implied value of about $3.41 per share. 30 August 2017
Pharmaceutical
The merger of two leading European drug discovery contract research organizations (CROs) has created the Mercachem-Syncom Group. 29 August 2017
Biotechnology
CSL Behring, a subsidiary of Australia’s CSL Limited, has agreed to acquire Calimmune, a US biotechnology company focused on the development of ex vivo hematopoietic stem cell (HSC) gene therapy with R&D facilities in Pasadena, California, and Sydney, Australia. 29 August 2017
Biotechnology
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Biotechnology
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Biotechnology
Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. 30 October 2024
Biotechnology
German drugmaker Dr Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company focusing on the development of novel KMO inhibitors for acute and chronic inflammatory diseases. 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Biotechnology
California, USA-based Lyell Immunopharma (Nasdaq: LYEL) has entered into a definitive agreement to acquire privately-held US CAR-T company ImmPACT Bio. 26 October 2024
Biotechnology
Mumbai-based Mankind Pharma has completed its acquisition of Bharat Serums and Vaccines (BSV), adding to its portfolio in the women’s health and fertility market. 24 October 2024
Biotechnology
Ocuphire Pharma has announced its acquisition of Opus Genetics, a clinical-stage gene therapy company focused on treating inherited retinal diseases. 24 October 2024
Biotechnology
Connecticut, USA-based Modifi Biosciences today announced that the company has been acquired by pharma giant Merck & Co 23 October 2024
Pharmaceutical
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Pharmaceutical
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Pharmaceutical
Last week’s significant news included Denmark-based CNS drugmaker Lundbeck reaching agreement to acquire US firm Longboard Pharmaceuticals, along with its bexicaserin, for $2.6 billion. Also, US pharma giant Pfizer entered into a deal with TRIANA Biomedicines to develop molecular glue degraders. On the regulatory front, the US Food and Drug Administration (FDA) last week approved Novocure’s key product Optune Lua for lung cancer patients. Also, German biotech BioNTech and its US partner OncoC4 received a partial clinical hold from the FDA on the Phase III trial of gotistobart in lung cancer. The European Medicines Agency’s human health committee, CHMP, Reaffirmed its non-approval of PTC Therapeutic’s Translarna. 20 October 2024
Biotechnology
Taiwan-based REGiMMUNE, a biopharma creating immunotherapies through the power of regulatory T cells (Tregs), and France-based Kiji Therapeutics, a specialist in induced pluripotent stem cells-mesenchymal stem cells (IPSC-MSC) engineered cell therapies for inflammatory diseases, are to merge. 18 October 2024
Biotechnology
Danish CNS specialist Lundbeck today revealed that it has reached to acquire Longboard Pharmaceuticals. 15 October 2024
Biotechnology
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze